Medtronic PLC (MDT), a leading medical device company, saw its stock plunge 5.18% in pre-market trading on Tuesday, following the release of its fiscal third-quarter 2025 earnings results.
The company reported revenue of $8.292 billion for the quarter ended January 24, 2025, slightly missing analyst estimates of $8.324 billion. The GAAP diluted earnings per share (EPS) came in at $1.01, lower than the expected $1.07. Although Medtronic reported non-GAAP diluted EPS of $1.39, beating estimates of $1.36, the overall results fell short of market expectations.
According to the earnings report, Medtronic faced challenges in its Medical Surgical Portfolio, which saw a 1.9% revenue decline attributed to pressures in the stapling segment and changes in distributor buying patterns. However, the company's Cardiovascular, Neuroscience, and Diabetes portfolios showed growth, with the Diabetes segment reporting an impressive 8.4% revenue increase driven by the adoption of the MiniMed™ 780G system.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。